Vaccine stocks surge as WHO declares a global emergency over the mpox outbreak.
The market’s disturbing response to human suffering highlights an uncomfortable truth.
The mpox crisis raises the usual questions about profit motives in healthcare.
FM
As the WHO declares a global health emergency over the mpox outbreak,
vaccine makers' stocks are surging. Is profiting from human misery the new
normal?
The Grim Reality: Mpox and the Surge in Vaccine Stocks
The recent declaration of a global health emergency by the World Health
Organization (WHO) in response to the escalating mpox outbreak in Africa has
sent shockwaves through the financial markets. But, alongside the cry
for humanitarian aid and global cooperation, the immediate reaction from the
markets was a surge in vaccine company stocks as investors and traders sought to benefit from the surge in demand. This isn’t a blip on the radar,
it’s a clear example of how the market capitalizes on crises, with a chilling
focus on human suffering.
Mpox has spread from Congo to neighbouring countries, including Burundi, Kenya, Rwanda and Uganda, prompting the WHO to declare the outbreak of the disease a global public health emergency https://t.co/9zZBEST12Gpic.twitter.com/2zYrF88om2
As investors rush to capitalize on the potential windfall from the
crisis, shares in vaccine manufacturers have soared. Companies like Bavarian
Nordic and Emergent BioSolutions have seen significant
upticks in their stock prices following the WHO's emergency declaration.
Bavarian Nordic, which produces the only FDA-approved vaccine for mpox,
witnessed a surge in its stock value, while Emergent BioSolutions, a key player
in vaccine production, saw similar gains. Other companies producing medical
tools used in the production or administration of vaccines have also seen
upticks.
Let’s not mince words: the market’s enthusiastic response to the mpox
emergency is pretty grim, though predictable. It's a stark reminder of how the
financial system often operates with a moral compass that’s spinning wildly out
of control. The surge in vaccine stocks isn't about hope or relief; it’s about
profit—cold, hard cash made off the back of a public health crisis.
This pattern is nothing new. The pharmaceutical industry has a long
history of reaping massive profits from global health crises. The Covid-19
pandemic was a prime example, with companies like Pfizer and
Moderna enjoying unprecedented stock gains. But the current response to the
mpox outbreak feels even more unsettling, given the slow, inadequate response
to the needs of those suffering from the disease.
Remembering Martin Shkreli
Martin Shkreli (Photo: Bloomberg)
If this all sounds familiar, it’s because it is. Just consider the case
of Martin Shkreli and the infamous Daraprim price hike. In 2015, Shkreli, then
CEO of Turing Pharmaceuticals, jacked up the price of Daraprim—a life-saving
drug used to treat parasitic infections—from $13.50 to $750 per pill overnight.
The public outrage was swift, but so was the financial windfall for Shkreli, a
famed lover of Kayne West, and his company.
The conditions are different, for sure, but the idea of actively profiting
off suffering, especially given the curative nature of the products produced by
the vaccine manufacturers, makes it stick in the throat. One key difference? This
time, it’s the entire market that’s jumping on the bandwagon, making the
exploitation of a public health crisis a norm rather than an anomaly.
The Mpox Emergency: A Lesson in Unchecked Capitalism
The current surge in vaccine stocks raises uncomfortable questions
about the nature of capitalism, particularly in the healthcare sector. When the
market rewards companies for merely being in the right place at the right time,
it becomes clear that profit, not people, is the driving force.
The WHO’s declaration of a global health emergency over the mpox
outbreak was meant to mobilize resources, encourage cooperation, and prompt
action, it wasn’t meant to be an indication that investors should line their
pockets. This is not just an indictment of the market, but of the entire
economic system that allows such behavior to thrive.
Looking Forward
So, where do we go from here? For starters, it’s crucial to recognize
that the current model of profit-driven healthcare is fundamentally flawed.
When life-saving treatments and vaccines are treated as commodities rather than
public goods, the result is a system that prioritizes profit over people.
But beyond policy changes, there needs to be a cultural shift—a
rethinking of the values that underpin our economic system. The idea that it’s
acceptable to profit from human suffering should be rejected outright. We need
to move towards a model of healthcare that is centered on equity, access, and
the well-being of all people, not just the bottom line.
We can but hope, right?
To wrap it all up, the surge in vaccine stocks following the mpox emergency
declaration is a disturbing reflection of our times. It highlights a systemic
problem where human suffering is just another opportunity for profit. As we
navigate through this crisis, it’s crucial to ask ourselves: what kind of
society do we want to be? One that profits from pain, or one that prioritizes
people over profit?
For more finance-adjacent stories, follow our Trending section.
As the WHO declares a global health emergency over the mpox outbreak,
vaccine makers' stocks are surging. Is profiting from human misery the new
normal?
The Grim Reality: Mpox and the Surge in Vaccine Stocks
The recent declaration of a global health emergency by the World Health
Organization (WHO) in response to the escalating mpox outbreak in Africa has
sent shockwaves through the financial markets. But, alongside the cry
for humanitarian aid and global cooperation, the immediate reaction from the
markets was a surge in vaccine company stocks as investors and traders sought to benefit from the surge in demand. This isn’t a blip on the radar,
it’s a clear example of how the market capitalizes on crises, with a chilling
focus on human suffering.
Mpox has spread from Congo to neighbouring countries, including Burundi, Kenya, Rwanda and Uganda, prompting the WHO to declare the outbreak of the disease a global public health emergency https://t.co/9zZBEST12Gpic.twitter.com/2zYrF88om2
As investors rush to capitalize on the potential windfall from the
crisis, shares in vaccine manufacturers have soared. Companies like Bavarian
Nordic and Emergent BioSolutions have seen significant
upticks in their stock prices following the WHO's emergency declaration.
Bavarian Nordic, which produces the only FDA-approved vaccine for mpox,
witnessed a surge in its stock value, while Emergent BioSolutions, a key player
in vaccine production, saw similar gains. Other companies producing medical
tools used in the production or administration of vaccines have also seen
upticks.
Let’s not mince words: the market’s enthusiastic response to the mpox
emergency is pretty grim, though predictable. It's a stark reminder of how the
financial system often operates with a moral compass that’s spinning wildly out
of control. The surge in vaccine stocks isn't about hope or relief; it’s about
profit—cold, hard cash made off the back of a public health crisis.
This pattern is nothing new. The pharmaceutical industry has a long
history of reaping massive profits from global health crises. The Covid-19
pandemic was a prime example, with companies like Pfizer and
Moderna enjoying unprecedented stock gains. But the current response to the
mpox outbreak feels even more unsettling, given the slow, inadequate response
to the needs of those suffering from the disease.
Remembering Martin Shkreli
Martin Shkreli (Photo: Bloomberg)
If this all sounds familiar, it’s because it is. Just consider the case
of Martin Shkreli and the infamous Daraprim price hike. In 2015, Shkreli, then
CEO of Turing Pharmaceuticals, jacked up the price of Daraprim—a life-saving
drug used to treat parasitic infections—from $13.50 to $750 per pill overnight.
The public outrage was swift, but so was the financial windfall for Shkreli, a
famed lover of Kayne West, and his company.
The conditions are different, for sure, but the idea of actively profiting
off suffering, especially given the curative nature of the products produced by
the vaccine manufacturers, makes it stick in the throat. One key difference? This
time, it’s the entire market that’s jumping on the bandwagon, making the
exploitation of a public health crisis a norm rather than an anomaly.
The Mpox Emergency: A Lesson in Unchecked Capitalism
The current surge in vaccine stocks raises uncomfortable questions
about the nature of capitalism, particularly in the healthcare sector. When the
market rewards companies for merely being in the right place at the right time,
it becomes clear that profit, not people, is the driving force.
The WHO’s declaration of a global health emergency over the mpox
outbreak was meant to mobilize resources, encourage cooperation, and prompt
action, it wasn’t meant to be an indication that investors should line their
pockets. This is not just an indictment of the market, but of the entire
economic system that allows such behavior to thrive.
Looking Forward
So, where do we go from here? For starters, it’s crucial to recognize
that the current model of profit-driven healthcare is fundamentally flawed.
When life-saving treatments and vaccines are treated as commodities rather than
public goods, the result is a system that prioritizes profit over people.
But beyond policy changes, there needs to be a cultural shift—a
rethinking of the values that underpin our economic system. The idea that it’s
acceptable to profit from human suffering should be rejected outright. We need
to move towards a model of healthcare that is centered on equity, access, and
the well-being of all people, not just the bottom line.
We can but hope, right?
To wrap it all up, the surge in vaccine stocks following the mpox emergency
declaration is a disturbing reflection of our times. It highlights a systemic
problem where human suffering is just another opportunity for profit. As we
navigate through this crisis, it’s crucial to ask ourselves: what kind of
society do we want to be? One that profits from pain, or one that prioritizes
people over profit?
For more finance-adjacent stories, follow our Trending section.
Louis Parks has lived and worked in and around the Middle East for much of his professional career. He writes about the meeting of the tech and finance worlds.
Gold Price Prediction 2026: WGC Warns of 20% Crash Risk
Featured Videos
Executive Interview | Charlotte Bullock | Chief Product Officer, Bank of London | FMLS:25
Executive Interview | Charlotte Bullock | Chief Product Officer, Bank of London | FMLS:25
Executive Interview | Charlotte Bullock | Chief Product Officer, Bank of London | FMLS:25
Executive Interview | Charlotte Bullock | Chief Product Officer, Bank of London | FMLS:25
In this interview, we sat down with Charlotte Bullock, Head of Product at The Bank of London, previously at SAP and now shaping product at one of the sector’s most ambitious new banking players.
Charlotte reflects on the Summit so far and talks about the culture inside fintech banks today. We look at the pressures that come with scaling, and how firms can hold onto the nimble approach that made them stand out early on.
We also cover the state of payments ahead of her appearance on the payments roundtable: the blockages financial firms face, the areas that still need fixing, and what a realistic solution looks like in 2026.
In this interview, we sat down with Charlotte Bullock, Head of Product at The Bank of London, previously at SAP and now shaping product at one of the sector’s most ambitious new banking players.
Charlotte reflects on the Summit so far and talks about the culture inside fintech banks today. We look at the pressures that come with scaling, and how firms can hold onto the nimble approach that made them stand out early on.
We also cover the state of payments ahead of her appearance on the payments roundtable: the blockages financial firms face, the areas that still need fixing, and what a realistic solution looks like in 2026.
In this interview, we sat down with Charlotte Bullock, Head of Product at The Bank of London, previously at SAP and now shaping product at one of the sector’s most ambitious new banking players.
Charlotte reflects on the Summit so far and talks about the culture inside fintech banks today. We look at the pressures that come with scaling, and how firms can hold onto the nimble approach that made them stand out early on.
We also cover the state of payments ahead of her appearance on the payments roundtable: the blockages financial firms face, the areas that still need fixing, and what a realistic solution looks like in 2026.
In this interview, we sat down with Charlotte Bullock, Head of Product at The Bank of London, previously at SAP and now shaping product at one of the sector’s most ambitious new banking players.
Charlotte reflects on the Summit so far and talks about the culture inside fintech banks today. We look at the pressures that come with scaling, and how firms can hold onto the nimble approach that made them stand out early on.
We also cover the state of payments ahead of her appearance on the payments roundtable: the blockages financial firms face, the areas that still need fixing, and what a realistic solution looks like in 2026.
In this conversation, we sit down with Drew Niv, CSO at ATFX Connect and one of the most influential figures in modern FX.
We speak about market structure, the institutional view on liquidity, and the sharp rise of prop trading, a sector Drew has been commenting on in recent months. Drew explains why he once dismissed prop trading, why his view changed, and what he now thinks the model means for brokers, clients and risk managers.
We explore subscription-fee dependency, the high reneging rate, and the long-term challenge: how brokers can build a more stable and honest version of the model. Drew also talks about the traffic advantage standalone prop firms have built and why brokers may still win in the long run if they take the right approach.
In this conversation, we sit down with Drew Niv, CSO at ATFX Connect and one of the most influential figures in modern FX.
We speak about market structure, the institutional view on liquidity, and the sharp rise of prop trading, a sector Drew has been commenting on in recent months. Drew explains why he once dismissed prop trading, why his view changed, and what he now thinks the model means for brokers, clients and risk managers.
We explore subscription-fee dependency, the high reneging rate, and the long-term challenge: how brokers can build a more stable and honest version of the model. Drew also talks about the traffic advantage standalone prop firms have built and why brokers may still win in the long run if they take the right approach.
In this conversation, we sit down with Drew Niv, CSO at ATFX Connect and one of the most influential figures in modern FX.
We speak about market structure, the institutional view on liquidity, and the sharp rise of prop trading, a sector Drew has been commenting on in recent months. Drew explains why he once dismissed prop trading, why his view changed, and what he now thinks the model means for brokers, clients and risk managers.
We explore subscription-fee dependency, the high reneging rate, and the long-term challenge: how brokers can build a more stable and honest version of the model. Drew also talks about the traffic advantage standalone prop firms have built and why brokers may still win in the long run if they take the right approach.
In this conversation, we sit down with Drew Niv, CSO at ATFX Connect and one of the most influential figures in modern FX.
We speak about market structure, the institutional view on liquidity, and the sharp rise of prop trading, a sector Drew has been commenting on in recent months. Drew explains why he once dismissed prop trading, why his view changed, and what he now thinks the model means for brokers, clients and risk managers.
We explore subscription-fee dependency, the high reneging rate, and the long-term challenge: how brokers can build a more stable and honest version of the model. Drew also talks about the traffic advantage standalone prop firms have built and why brokers may still win in the long run if they take the right approach.
In this conversation, we sit down with Drew Niv, CSO at ATFX Connect and one of the most influential figures in modern FX.
We speak about market structure, the institutional view on liquidity, and the sharp rise of prop trading, a sector Drew has been commenting on in recent months. Drew explains why he once dismissed prop trading, why his view changed, and what he now thinks the model means for brokers, clients and risk managers.
We explore subscription-fee dependency, the high reneging rate, and the long-term challenge: how brokers can build a more stable and honest version of the model. Drew also talks about the traffic advantage standalone prop firms have built and why brokers may still win in the long run if they take the right approach.
In this conversation, we sit down with Drew Niv, CSO at ATFX Connect and one of the most influential figures in modern FX.
We speak about market structure, the institutional view on liquidity, and the sharp rise of prop trading, a sector Drew has been commenting on in recent months. Drew explains why he once dismissed prop trading, why his view changed, and what he now thinks the model means for brokers, clients and risk managers.
We explore subscription-fee dependency, the high reneging rate, and the long-term challenge: how brokers can build a more stable and honest version of the model. Drew also talks about the traffic advantage standalone prop firms have built and why brokers may still win in the long run if they take the right approach.
Executive Interview | Remonda Z. Kirketerp Møller| CEO & Founder Muinmos | FMLS:25
Executive Interview | Remonda Z. Kirketerp Møller| CEO & Founder Muinmos | FMLS:25
Executive Interview | Remonda Z. Kirketerp Møller| CEO & Founder Muinmos | FMLS:25
Executive Interview | Remonda Z. Kirketerp Møller| CEO & Founder Muinmos | FMLS:25
Executive Interview | Remonda Z. Kirketerp Møller| CEO & Founder Muinmos | FMLS:25
Executive Interview | Remonda Z. Kirketerp Møller| CEO & Founder Muinmos | FMLS:25
In this interview, Remonda Z. Kirketerp Møller, founder of Muinmos, breaks down the state of AI in regtech and what responsible adoption really looks like for brokers. We talk about rising fragmentation, the pressures around compliance accuracy, and why most firms are still in the early stages of AI maturity.
Ramanda also shares insights on regulator sandboxes, shifting expectations around accountability, and the current reality of MiCA licensing and passporting in Europe.
A concise look at where compliance, onboarding, and AI-driven processes are heading next.
In this interview, Remonda Z. Kirketerp Møller, founder of Muinmos, breaks down the state of AI in regtech and what responsible adoption really looks like for brokers. We talk about rising fragmentation, the pressures around compliance accuracy, and why most firms are still in the early stages of AI maturity.
Ramanda also shares insights on regulator sandboxes, shifting expectations around accountability, and the current reality of MiCA licensing and passporting in Europe.
A concise look at where compliance, onboarding, and AI-driven processes are heading next.
In this interview, Remonda Z. Kirketerp Møller, founder of Muinmos, breaks down the state of AI in regtech and what responsible adoption really looks like for brokers. We talk about rising fragmentation, the pressures around compliance accuracy, and why most firms are still in the early stages of AI maturity.
Ramanda also shares insights on regulator sandboxes, shifting expectations around accountability, and the current reality of MiCA licensing and passporting in Europe.
A concise look at where compliance, onboarding, and AI-driven processes are heading next.
In this interview, Remonda Z. Kirketerp Møller, founder of Muinmos, breaks down the state of AI in regtech and what responsible adoption really looks like for brokers. We talk about rising fragmentation, the pressures around compliance accuracy, and why most firms are still in the early stages of AI maturity.
Ramanda also shares insights on regulator sandboxes, shifting expectations around accountability, and the current reality of MiCA licensing and passporting in Europe.
A concise look at where compliance, onboarding, and AI-driven processes are heading next.
In this interview, Remonda Z. Kirketerp Møller, founder of Muinmos, breaks down the state of AI in regtech and what responsible adoption really looks like for brokers. We talk about rising fragmentation, the pressures around compliance accuracy, and why most firms are still in the early stages of AI maturity.
Ramanda also shares insights on regulator sandboxes, shifting expectations around accountability, and the current reality of MiCA licensing and passporting in Europe.
A concise look at where compliance, onboarding, and AI-driven processes are heading next.
In this interview, Remonda Z. Kirketerp Møller, founder of Muinmos, breaks down the state of AI in regtech and what responsible adoption really looks like for brokers. We talk about rising fragmentation, the pressures around compliance accuracy, and why most firms are still in the early stages of AI maturity.
Ramanda also shares insights on regulator sandboxes, shifting expectations around accountability, and the current reality of MiCA licensing and passporting in Europe.
A concise look at where compliance, onboarding, and AI-driven processes are heading next.
In this conversation, we speak with Aydin Bonabi, CEO and co-founder of Surveill, a firm focused on fraud detection and AI-driven compliance tools for financial institutions.
We start with Aydin’s view of the Summit and the challenges brokers face as fraud tactics grow more complex. He explains how firms can stay ahead through real-time signals, data patterns, and early-stage detection.
We also talk about AI training and why compliance teams often struggle to keep models accurate, fair, and aligned with regulatory expectations. Aydin breaks down what “good” AI training looks like inside a financial environment, including the importance of clean data, domain expertise, and human oversight.
He closes with a clear message: fraud is scaling, and so must the tools that stop it.
In this conversation, we speak with Aydin Bonabi, CEO and co-founder of Surveill, a firm focused on fraud detection and AI-driven compliance tools for financial institutions.
We start with Aydin’s view of the Summit and the challenges brokers face as fraud tactics grow more complex. He explains how firms can stay ahead through real-time signals, data patterns, and early-stage detection.
We also talk about AI training and why compliance teams often struggle to keep models accurate, fair, and aligned with regulatory expectations. Aydin breaks down what “good” AI training looks like inside a financial environment, including the importance of clean data, domain expertise, and human oversight.
He closes with a clear message: fraud is scaling, and so must the tools that stop it.
In this conversation, we speak with Aydin Bonabi, CEO and co-founder of Surveill, a firm focused on fraud detection and AI-driven compliance tools for financial institutions.
We start with Aydin’s view of the Summit and the challenges brokers face as fraud tactics grow more complex. He explains how firms can stay ahead through real-time signals, data patterns, and early-stage detection.
We also talk about AI training and why compliance teams often struggle to keep models accurate, fair, and aligned with regulatory expectations. Aydin breaks down what “good” AI training looks like inside a financial environment, including the importance of clean data, domain expertise, and human oversight.
He closes with a clear message: fraud is scaling, and so must the tools that stop it.
In this conversation, we speak with Aydin Bonabi, CEO and co-founder of Surveill, a firm focused on fraud detection and AI-driven compliance tools for financial institutions.
We start with Aydin’s view of the Summit and the challenges brokers face as fraud tactics grow more complex. He explains how firms can stay ahead through real-time signals, data patterns, and early-stage detection.
We also talk about AI training and why compliance teams often struggle to keep models accurate, fair, and aligned with regulatory expectations. Aydin breaks down what “good” AI training looks like inside a financial environment, including the importance of clean data, domain expertise, and human oversight.
He closes with a clear message: fraud is scaling, and so must the tools that stop it.
In this conversation, we speak with Aydin Bonabi, CEO and co-founder of Surveill, a firm focused on fraud detection and AI-driven compliance tools for financial institutions.
We start with Aydin’s view of the Summit and the challenges brokers face as fraud tactics grow more complex. He explains how firms can stay ahead through real-time signals, data patterns, and early-stage detection.
We also talk about AI training and why compliance teams often struggle to keep models accurate, fair, and aligned with regulatory expectations. Aydin breaks down what “good” AI training looks like inside a financial environment, including the importance of clean data, domain expertise, and human oversight.
He closes with a clear message: fraud is scaling, and so must the tools that stop it.
In this conversation, we speak with Aydin Bonabi, CEO and co-founder of Surveill, a firm focused on fraud detection and AI-driven compliance tools for financial institutions.
We start with Aydin’s view of the Summit and the challenges brokers face as fraud tactics grow more complex. He explains how firms can stay ahead through real-time signals, data patterns, and early-stage detection.
We also talk about AI training and why compliance teams often struggle to keep models accurate, fair, and aligned with regulatory expectations. Aydin breaks down what “good” AI training looks like inside a financial environment, including the importance of clean data, domain expertise, and human oversight.
He closes with a clear message: fraud is scaling, and so must the tools that stop it.
Exness expands its presence in Africa: Inside our interview with Paul Margarites in Cape Town
Exness expands its presence in Africa: Inside our interview with Paul Margarites in Cape Town
Exness expands its presence in Africa: Inside our interview with Paul Margarites in Cape Town
Exness expands its presence in Africa: Inside our interview with Paul Margarites in Cape Town
Exness expands its presence in Africa: Inside our interview with Paul Margarites in Cape Town
Exness expands its presence in Africa: Inside our interview with Paul Margarites in Cape Town
Finance Magnates met with Paul Margarites, Exness regional commercial director for Sub-Saharan Africa, during a visit to the firm’s office opening in Cape Town. In this talk, led by Andrea Badiola Mateos, Co-CEO at Finance Magnates, Paul shares views on the South African trading space, local user behavior, mobile trends, regulation, team growth, and how Exness plans to grow in more markets across the region. @Exness
Read the article at: https://www.financemagnates.com/thought-leadership/exness-expands-its-presence-in-africa-inside-our-interview-with-paul-margarites/
#exness #financemagnates #exnesstrading #CFDtrading #tradeonline #africanews #capetown
Finance Magnates met with Paul Margarites, Exness regional commercial director for Sub-Saharan Africa, during a visit to the firm’s office opening in Cape Town. In this talk, led by Andrea Badiola Mateos, Co-CEO at Finance Magnates, Paul shares views on the South African trading space, local user behavior, mobile trends, regulation, team growth, and how Exness plans to grow in more markets across the region. @Exness
Read the article at: https://www.financemagnates.com/thought-leadership/exness-expands-its-presence-in-africa-inside-our-interview-with-paul-margarites/
#exness #financemagnates #exnesstrading #CFDtrading #tradeonline #africanews #capetown
Finance Magnates met with Paul Margarites, Exness regional commercial director for Sub-Saharan Africa, during a visit to the firm’s office opening in Cape Town. In this talk, led by Andrea Badiola Mateos, Co-CEO at Finance Magnates, Paul shares views on the South African trading space, local user behavior, mobile trends, regulation, team growth, and how Exness plans to grow in more markets across the region. @Exness
Read the article at: https://www.financemagnates.com/thought-leadership/exness-expands-its-presence-in-africa-inside-our-interview-with-paul-margarites/
#exness #financemagnates #exnesstrading #CFDtrading #tradeonline #africanews #capetown
Finance Magnates met with Paul Margarites, Exness regional commercial director for Sub-Saharan Africa, during a visit to the firm’s office opening in Cape Town. In this talk, led by Andrea Badiola Mateos, Co-CEO at Finance Magnates, Paul shares views on the South African trading space, local user behavior, mobile trends, regulation, team growth, and how Exness plans to grow in more markets across the region. @Exness
Read the article at: https://www.financemagnates.com/thought-leadership/exness-expands-its-presence-in-africa-inside-our-interview-with-paul-margarites/
#exness #financemagnates #exnesstrading #CFDtrading #tradeonline #africanews #capetown
Finance Magnates met with Paul Margarites, Exness regional commercial director for Sub-Saharan Africa, during a visit to the firm’s office opening in Cape Town. In this talk, led by Andrea Badiola Mateos, Co-CEO at Finance Magnates, Paul shares views on the South African trading space, local user behavior, mobile trends, regulation, team growth, and how Exness plans to grow in more markets across the region. @Exness
Read the article at: https://www.financemagnates.com/thought-leadership/exness-expands-its-presence-in-africa-inside-our-interview-with-paul-margarites/
#exness #financemagnates #exnesstrading #CFDtrading #tradeonline #africanews #capetown
Finance Magnates met with Paul Margarites, Exness regional commercial director for Sub-Saharan Africa, during a visit to the firm’s office opening in Cape Town. In this talk, led by Andrea Badiola Mateos, Co-CEO at Finance Magnates, Paul shares views on the South African trading space, local user behavior, mobile trends, regulation, team growth, and how Exness plans to grow in more markets across the region. @Exness
Read the article at: https://www.financemagnates.com/thought-leadership/exness-expands-its-presence-in-africa-inside-our-interview-with-paul-margarites/
#exness #financemagnates #exnesstrading #CFDtrading #tradeonline #africanews #capetown
